The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

Bravo Vergel, Y; Hawkins, NS; Claxton, K; Asseburg, C; Palmer, S; Woolacott, N; Bruce, IN; Sculpher, MJ; (2007) The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford, England), 46. pp. 1729-35. ISSN 1462-0324 DOI: https://doi.org/10.1093/rheumatology/kem221

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1093/rheumatology/kem221

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar